PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016

(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the Annals of Internal Medicine.

Noting that that inhibit PCSK9 are an emerging therapy for dyslipidemia, Eliano P. Navarese, M.D., Ph.D., from Heinrich Heine University in Düsseldorf, Germany, and colleagues reviewed the literature to discuss the use of PCSK9 antibodies in patients with ACS.

The researchers note that levels of PCSK9 increase in ACS. PCSK9 antibodies can have a dual effect in improving clinical outcomes, with a reduction in lipid fraction and inhibition of PCSK9. Acute inhibition may benefit patients via several mechanisms, including the reduction of low-density lipoprotein (LDL) cholesterol levels. In addition, PCSK9 inhibition was associated with anti-inflammatory and antiplatelet effects that could result in direct plaque stabilization, conferring early benefit.

"Despite the robust clinical rationale and preclinical data that support the potential benefit of PCSK9 antibodies beyond reduction of LDL cholesterol levels in ACS, further studies are required to confirm this hypothesis," the authors write. "To definitively demonstrate that PCSK9 antibodies have dual antidyslipidemic and plaque-stabilizing effects in the early phase of ACS that may translate into improved , a large-scale, randomized, controlled trial powered for clinical end points is needed."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: New class of cholesterol drug proves safe and effective for patients with dyslipidemia

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

New class of cholesterol drug proves safe and effective for patients with dyslipidemia

April 27, 2015
Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published ...

US regulators give limited approval to cholesterol drug

July 25, 2015
US regulators on Friday approved a new cholesterol drug called Praluent, made by Sanofi and Regeneron, for people with certain genetic risk factors for heart disease.

Could a protein be linked to heart attacks?

September 3, 2014
A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact ...

Enzyme may be key to stopping fatal sepsis outcomes

October 16, 2014
University of British Columbia led research has discovered that controlling levels of the human enzyme PCSK9 could be the difference between life and death for patients with severe sepsis.

New class of drugs lowers cholesterol in first human trial

October 2, 2013
A single dose of the small interfering ribonucleic acid (siRNA) drug candidate ALN-PCS cut levels of LDL cholesterol (bad cholesterol) in healthy volunteers by up to 57%, and 40% on average more than those given a placebo, ...

Researchers develop vaccine to treat high cholesterol

October 14, 2015
A team of researchers at the University of New Mexico (UNM) and the National Institutes of Health (NIH) have developed a vaccine to treat high cholesterol. The vaccine, which targets a molecule called PCSK9, a protein involved ...

Recommended for you

Noisy workplace may wreak havoc on your heart

March 22, 2018
(HealthDay)—Loud noise at work doesn't just threaten your hearing, it might also boost your blood pressure and cholesterol levels, a new U.S. government report suggests.

Smartwatch effective in detecting atrial fibrillation

March 22, 2018
Irregular heart impulses that lead to stroke can be detected with great accuracy using a smartwatch with a specially designed application, a finding that could eventually lead to new ways to screen patients for earlier treatment, ...

AI is quicker, more effective than humans in analyzing heart scans

March 22, 2018
A type of artificial intelligence known as advanced machine learning can classify essential views from heart ultrasound tests faster, more accurately and with less data than board-certified echocardiographers, according to ...

Majority of U.S. adults have poor heart health: study

March 19, 2018
(HealthDay)—America's heart health went from bad to worse between 1988 and 2014, a new report warns.

Drinking alcohol makes your heart race

March 18, 2018
The more alcohol you drink, the higher your heart rate gets, according to research presented today at EHRA 2018 Congress, organized by the European Society of Cardiology.

Study of nearly 300,000 people challenges the 'obesity paradox'

March 15, 2018
The idea that it might be possible to be overweight or obese but not at increased risk of heart disease, otherwise known as the "obesity paradox", has been challenged by a study of nearly 300,000 people published in in the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.